ARTICLE | Clinical News
Arbaclofen regulatory update
October 5, 2015 7:00 AM UTC
FDA accepted for review an NDA from Osmotica for Ontinua ER arbaclofen to treat spasticity in patients with multiple sclerosis (MS). Osmotica declined to disclose the PDUFA date. The product is an ext...